What is iCAD?
iCAD, Inc. (NASDAQ: ICAD) is dedicated to eradicating the threat of cancer by providing clinically validated AI-driven solutions that empower medical professionals to achieve earlier and more precise cancer detection, ultimately improving patient outcomes. Based in Nashua, N.H., iCAD's flagship ProFound Breast Health Suite leverages artificial intelligence to enhance mammography analysis, facilitating accurate breast cancer detection, density assessment, and risk evaluation. The company's mission is to ensure that cancer cannot hide, making advanced diagnostic tools accessible and effective.
How much funding has iCAD raised?
iCAD has raised a total of $37.8M across 3 funding rounds:
Share Placement
$15M
Stock Offering
$10.3M
Stock Offering
$12.5M
Share Placement (2012): $15M with participation from Deerfield
Stock Issuance/Offering (2019): $10.3M, investors not publicly disclosed
Stock Issuance/Offering (2020): $12.5M, investors not publicly disclosed
Key Investors in iCAD
Deerfield
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy. The firm supports companies across the healthcare ecosystem with flexible funding models and drives innovation using AI, data, and market research.
What's next for iCAD?
With the recent infusion of major strategic capital, iCAD is poised for accelerated growth and further innovation in the competitive AI-driven medical diagnostics market. This significant investment is expected to fuel the expansion of its ProFound Breast Health Suite, enhance its research and development capabilities, and broaden its market reach globally. The company's focus on early detection and improved patient outcomes positions it for continued leadership and impact in the fight against cancer, with strategic partnerships and technological advancements likely to be key drivers in its future trajectory.
See full iCAD company page
